ES2137915T3 - Derivados de tiazolidindiona sustituida. - Google Patents

Derivados de tiazolidindiona sustituida.

Info

Publication number
ES2137915T3
ES2137915T3 ES88307910T ES88307910T ES2137915T3 ES 2137915 T3 ES2137915 T3 ES 2137915T3 ES 88307910 T ES88307910 T ES 88307910T ES 88307910 T ES88307910 T ES 88307910T ES 2137915 T3 ES2137915 T3 ES 2137915T3
Authority
ES
Spain
Prior art keywords
substituted
group
compounds
unsubstituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88307910T
Other languages
English (en)
Spanish (es)
Inventor
Richard Mark Hindley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2137915(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB878720825A external-priority patent/GB8720825D0/en
Priority claimed from GB878727987A external-priority patent/GB8727987D0/en
Priority claimed from GB888802454A external-priority patent/GB8802454D0/en
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Application granted granted Critical
Publication of ES2137915T3 publication Critical patent/ES2137915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
ES88307910T 1987-09-04 1988-08-26 Derivados de tiazolidindiona sustituida. Expired - Lifetime ES2137915T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878720825A GB8720825D0 (en) 1987-09-04 1987-09-04 Compounds
GB878727987A GB8727987D0 (en) 1987-11-30 1987-11-30 Novel compounds
GB888802454A GB8802454D0 (en) 1988-02-04 1988-02-04 Compounds

Publications (1)

Publication Number Publication Date
ES2137915T3 true ES2137915T3 (es) 2000-01-01

Family

ID=27263577

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88307910T Expired - Lifetime ES2137915T3 (es) 1987-09-04 1988-08-26 Derivados de tiazolidindiona sustituida.

Country Status (18)

Country Link
US (1) US5002953A (cg-RX-API-DMAC7.html)
EP (2) EP0306228B1 (cg-RX-API-DMAC7.html)
JP (6) JP2614497B2 (cg-RX-API-DMAC7.html)
KR (1) KR0164207B1 (cg-RX-API-DMAC7.html)
AT (1) ATE186724T1 (cg-RX-API-DMAC7.html)
AU (1) AU611938B2 (cg-RX-API-DMAC7.html)
CA (1) CA1328452C (cg-RX-API-DMAC7.html)
CZ (1) CZ391691A3 (cg-RX-API-DMAC7.html)
DE (2) DE10199003I1 (cg-RX-API-DMAC7.html)
DK (2) DK175176B1 (cg-RX-API-DMAC7.html)
ES (1) ES2137915T3 (cg-RX-API-DMAC7.html)
GR (1) GR3031873T3 (cg-RX-API-DMAC7.html)
IE (1) IE20000683A1 (cg-RX-API-DMAC7.html)
LU (1) LU90711I2 (cg-RX-API-DMAC7.html)
NL (1) NL300034I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ226027A (cg-RX-API-DMAC7.html)
PT (1) PT88410B (cg-RX-API-DMAC7.html)
SG (1) SG59988A1 (cg-RX-API-DMAC7.html)

Families Citing this family (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10199003I1 (de) * 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
ES2092539T3 (es) * 1991-01-10 1996-12-01 Transcend Therapeutics Inc Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
JP3053490B2 (ja) * 1991-02-25 2000-06-19 杏林製薬株式会社 チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US5589492A (en) * 1992-04-10 1996-12-31 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of Type-II diabetes
WO1993021166A1 (en) * 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
RU2134686C1 (ru) * 1992-07-03 1999-08-20 Смитклайн Бичам П.Л.С. Гетероциклическое соединение, или его таутомерная форма, и/или фармацевтически приемлемая соль, и/или фармацевтически приемлемый сольват, фармацевтическая композиция, снижающая содержание глюкозы в крови, способ лечения и/или профилактики гипергликемии
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
ZA936324B (en) * 1992-08-31 1994-03-22 Sankyo Co Oxazolidine derivatives having anti-diabetic and anti-obesity properties their preparation and their therapeutic uses
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5521202A (en) * 1993-04-07 1996-05-28 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivatives and pharmaceutical compositions containing the same
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
GB9311661D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9311644D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9315148D0 (en) * 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
AU679572B2 (en) * 1993-09-15 1997-07-03 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of NIDDM
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
MX9603338A (es) * 1994-02-10 1997-03-29 Smithkline Beecham Plc Uso de sensibilizadores a la insulina para tratar enfermedades renales.
RU2114844C1 (ru) * 1994-04-11 1998-07-10 Санкио Компани Лимитед Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
US5436373A (en) * 1994-10-26 1995-07-25 Elf Atochem North America, Inc. Process for the preparation of N-benzyl-N-organoaminoalkanol
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US5827865A (en) * 1995-03-09 1998-10-27 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
CZ318098A3 (cs) * 1996-04-04 1999-01-13 Sankyo Company, Limited Deriváty fenylalkylkarboxylové kyseliny, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
DE69625795T2 (de) * 1996-04-09 2003-08-14 Dr. Reddy's Laboratories Ltd., Hyderabad Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5889032A (en) * 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
WO1997043283A1 (de) * 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neues verfahren zur herstellung von troglitazone
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CN1221417A (zh) * 1996-07-26 1999-06-30 雷迪博士研究基金会 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
AU774839B2 (en) * 1997-02-18 2004-07-08 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione
UY24886A1 (es) * 1997-02-18 2001-08-27 Smithkline Beecham Plc Tiazolidindiona
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6011036A (en) * 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
DE69837089T2 (de) * 1997-06-18 2007-06-21 Smithkline Beecham P.L.C., Brentford Behandlung der diabetes mit thiazolidindion und sulfonylharnstoff
SI0996444T1 (sl) * 1997-06-18 2007-08-31 Smithkline Beecham Plc Zdravljenje diabetesa s tiazolidindionom in metforminom
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
TR200000896T2 (tr) 1997-10-02 2000-09-21 Sankyo Company Limited Amidokarboksilik asit türevleri.
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9723295D0 (en) * 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
ATE212991T1 (de) * 1997-12-02 2002-02-15 Reddy Research Foundation Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
EP1036075B1 (en) * 1997-12-02 2004-06-23 Dr. Reddy's Laboratories Ltd. Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties
WO1999030739A1 (en) * 1997-12-16 1999-06-24 Sankyo Company, Limited Leukemia remedy
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
ES2237929T3 (es) * 1998-07-21 2005-08-01 Smithkline Beecham Plc Uso del activador de la asimilacion de glucosa rosiglitazona para reducir la apoptosis inducida por isquemia de celulas beta pancreaticas, celulas endoteliales y celulas neuronales.
IN187716B (cg-RX-API-DMAC7.html) * 1998-09-14 2002-06-15 Reddy Research Foundation
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
AR023699A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AU3073700A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909075D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
PL351685A1 (en) * 1999-04-23 2003-06-02 Smithkline Beecham Plc Novel pharmaceutical
PE20010040A1 (es) 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
PE20010044A1 (es) 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
ATE365158T1 (de) 1999-04-28 2007-07-15 Inst Med Molecular Design Inc Pyrimidincarbonsäurederivate
GB9913782D0 (en) * 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
US6380191B1 (en) * 1999-06-18 2002-04-30 Merck & Co. Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
KR20020022812A (ko) * 1999-08-17 2002-03-27 피터 기딩스 티아졸리딘디온 유도체를 함유하는 제약 조성물 및 그의제조 방법
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
ES2156574B1 (es) * 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
CN1215059C (zh) 1999-12-03 2005-08-17 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
HU225919B1 (en) * 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
DE60132723T2 (de) 2000-01-21 2009-01-29 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
WO2001090356A1 (fr) * 2000-05-25 2001-11-29 Yamanouchi Pharmaceutical Co., Ltd. Promoteur de pgc-1 humain
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
WO2002024689A1 (en) 2000-09-21 2002-03-28 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
BR0114196A (pt) * 2000-09-26 2003-07-22 Reddy S Res Foundation Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0029125D0 (en) * 2000-11-29 2001-01-10 Specialistkliniken I Varberg H Novel treatment
US20040082620A1 (en) 2000-12-22 2004-04-29 Craig Andrew Simon 5'-4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002051823A1 (en) 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate
ATE341343T1 (de) * 2000-12-26 2006-10-15 Sankyo Co Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
ES2174748B1 (es) * 2001-01-31 2003-09-16 Vita Lab Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
JP4590159B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
KR100874677B1 (ko) * 2001-05-29 2008-12-18 교토 야쿠힝 고교 가부시키가이샤 신규 복소환 유도체 및 그 의약 용도
BR0209711A (pt) * 2001-05-29 2004-11-03 Kyoto Pharma Ind Composto heterocìclico e seu uso medicinal
JP4152641B2 (ja) * 2001-08-07 2008-09-17 クラシエ製薬株式会社 チアゾリジン誘導体の副作用軽減剤
WO2003029251A1 (en) * 2001-09-28 2003-04-10 Biocon Limited Novel process for the synthesis of thiazolidinedione derivatives
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352391A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0129851D0 (en) * 2001-12-13 2002-01-30 Smithkline Beecham Plc Novel compounds
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130510D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002366812A1 (en) * 2001-12-20 2003-07-09 Teva Pharmaceutical Industries Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
DE60304175T2 (de) * 2002-04-29 2007-03-15 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von losartan und losartan-kaliumsalz
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004089945A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Rosiglitazone derivatives as antidiabetic agents
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
JPWO2004106542A1 (ja) * 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
RS20050890A (sr) * 2003-05-30 2007-12-31 Ranbaxy Laboratories Limited, Supstituisani pirol derivati
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
AU2003269483A1 (en) * 2003-09-10 2005-03-29 Biocon Limited Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione
JP5140881B2 (ja) * 2003-09-17 2013-02-13 要 川杉 医薬組成物
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
WO2005073227A2 (en) * 2004-01-28 2005-08-11 Usv Limited A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
GB2421240A (en) * 2004-12-14 2006-06-21 Sandoz Ag Phosphoric acid salt of rosiglitazone
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
CN102134230B (zh) * 2004-03-15 2019-06-28 武田药品工业株式会社 二肽基肽酶抑制剂
WO2005092382A1 (ja) * 2004-03-29 2005-10-06 Sankyo Company, Limited インスリン抵抗性改善剤を含有する糖尿病治療剤
GB2413795A (en) * 2004-05-05 2005-11-09 Cipla Ltd Process for the preparation of rosiglitazone
EP1745043A1 (en) * 2004-05-12 2007-01-24 Medichem S.A. Process for the preparation of rosiglitazone
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
CZ297266B6 (cs) * 2004-09-10 2006-10-11 Zentiva, A. S. Zpusob prípravy rosiglitazonu
CZ297347B6 (cs) * 2004-09-21 2006-11-15 Zentiva, A. S. Zpusob prípravy rosiglitazonu
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
US20060122232A1 (en) * 2004-12-06 2006-06-08 Development Center For Biotechnology 4-Hydroxyfuroic acid derivatives
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
FR2887444A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
FR2887442A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzyl-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
JPWO2007007757A1 (ja) * 2005-07-12 2009-01-29 第一三共株式会社 ＰＰＡＲγアゴニストを含有する医薬組成物
ATE532518T1 (de) * 2005-09-14 2011-11-15 Takeda Pharmaceutical Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
CA2622642C (en) * 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
TW200730173A (en) * 2005-12-16 2007-08-16 Sankyo Co Pharmaceutical composition enhancing production of adiponectin
EP2029585A2 (en) * 2006-03-08 2009-03-04 Medichem, S.A. Process for preparation of intermediates of rosiglitazone, rosiglitazone and polymorphic forms thereof
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
KR20080106455A (ko) * 2006-03-31 2008-12-05 웰스태트 테러퓨틱스 코포레이션 대사장애의 조합치료
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
US20070293546A1 (en) * 2006-06-15 2007-12-20 Srinivasula Reddy Maddula Preparation of rosiglitazone and its salts
HUP0600517A3 (en) * 2006-06-23 2008-10-28 Richter Gedeon Nyrt Process for the production of benzylidene-rosiglitazone base
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
SI2073810T1 (sl) * 2006-09-13 2011-12-30 Takeda Pharmaceutical Uporaba 2-6(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin -1-ilmetil-4-fluoro-benzonitrila za zdravljenje diabetesa, raka, avtoimunskih motenj in infekcije s HIV
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CA2673418A1 (en) 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
WO2008091624A2 (en) * 2007-01-22 2008-07-31 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
JP4866901B2 (ja) 2007-02-07 2012-02-01 協和発酵キリン株式会社 ３環系化合物
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
KR20090126286A (ko) 2007-04-05 2009-12-08 다이이찌 산쿄 가부시키가이샤 축합 2 고리형 헤테로아릴 유도체
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX348799B (es) 2007-07-26 2017-06-29 Amgen Inc Enzimas aciltransferasa de lecitina-colesterol, modificadas.
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
PL384446A1 (pl) * 2008-02-12 2009-08-17 Adamed Spółka Z Ograniczoną Odpowiedzialnością Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010016549A1 (ja) 2008-08-06 2010-02-11 協和発酵キリン株式会社 ３環系化合物
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
HRP20140709T1 (hr) 2008-08-12 2014-09-26 Zinfandel Pharmaceuticals, Inc. Postupak identifikacije faktora rizika za alzheimerovu bolest
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
HUP0800755A2 (en) 2008-12-11 2010-09-28 Richter Gedeon Nyrt Crystalline forms of rosiglitazone
ES2617191T3 (es) 2009-03-05 2017-06-15 Daiichi Sankyo Company, Limited Derivado de piridina como inhibidor de PPARY
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
EP2552442A1 (en) 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
WO2012033091A1 (ja) 2010-09-07 2012-03-15 第一三共株式会社 安息香酸エステル類の製造法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
KR102171747B1 (ko) 2011-01-10 2020-11-04 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
TW201311678A (zh) 2011-08-03 2013-03-16 Kyowa Hakko Kirin Co Ltd 二苯并氧呯衍生物
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
MX368200B (es) 2011-12-08 2019-09-24 Amgen Inc Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia.
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
HK1214760A1 (zh) 2012-11-05 2016-08-05 Commissariat à l'énergie atomique et aux énergies alternatives 用於消除体内血癌干细胞以及用於防止血癌复发的抗癌试剂如酪氨酸激酶和stat5拮抗剂优选为噻唑烷二酮的组合
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
EP3568134A1 (en) 2017-01-16 2019-11-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
GR1010570B (el) * 2022-12-22 2023-11-17 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
DE10199003I1 (de) * 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate

Also Published As

Publication number Publication date
DK490288A (da) 1989-03-05
PT88410A (pt) 1989-07-31
EP0842925A1 (en) 1998-05-20
EP0306228A1 (en) 1989-03-08
US5002953A (en) 1991-03-26
PT88410B (pt) 1992-10-30
JP2837139B2 (ja) 1998-12-14
DE3856378D1 (de) 1999-12-23
LU90711I2 (fr) 2001-03-05
NL300034I2 (nl) 2001-05-01
DK200001556A (da) 2000-10-18
DK175176B1 (da) 2004-06-21
KR0164207B1 (ko) 1999-01-15
HK1011029A1 (en) 1999-07-02
DE10199003I2 (cg-RX-API-DMAC7.html) 2003-09-18
NZ226027A (en) 1992-03-26
KR890005095A (ko) 1989-05-11
DE10199003I1 (de) 2003-06-12
JP2614497B2 (ja) 1997-05-28
CZ391691A3 (en) 1993-03-17
DE3856378T2 (de) 2000-05-11
IE20000683A1 (en) 2002-07-24
JPH10194970A (ja) 1998-07-28
JPH09183771A (ja) 1997-07-15
NL300034I1 (nl) 2001-03-01
CA1328452C (en) 1994-04-12
ATE186724T1 (de) 1999-12-15
JP2817840B2 (ja) 1998-10-30
JPH01131169A (ja) 1989-05-24
DK490288D0 (da) 1988-09-02
EP0306228B1 (en) 1999-11-17
JPH10194971A (ja) 1998-07-28
AU611938B2 (en) 1991-06-27
JPH09183772A (ja) 1997-07-15
SG59988A1 (en) 1999-02-22
GR3031873T3 (en) 2000-02-29
JPH09183726A (ja) 1997-07-15
AU2173888A (en) 1989-03-09

Similar Documents

Publication Publication Date Title
ES2137915T3 (es) Derivados de tiazolidindiona sustituida.
ATE102193T1 (de) Thiazolidinedionederivate.
ATE118487T1 (de) Thiazolidinedionederivate.
FI950016A0 (fi) Heterosykliset yhdisteet lääkeaineena
ES2044836T3 (es) Derivado de la piperidina, su utilizacion y compuesto farmaceutico que lo contiene.
EP0356214A3 (en) Thiazolidine dione derivatives
DK0695183T3 (da) Anvendelse af thiazolidindioner til behandling af atherosklerose og spiseforstyrrelser
IL77452A0 (en) Derivatives of arylcyclobutylalkylamines,their preparation and pharmaceutical compositions containing them
ATE123487T1 (de) Derivate der kaffeinsäure und sie enthaltende pharmazeutische zusammensetzungen.
NO872982L (no) Nye tetracykliske indolderivater.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 306228

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: ROSIGLITAZONA (AVANDIA)

Spc suppl protection certif: C200100002

Filing date: 20010110

SPCG Supplementary protection certificate granted

Free format text: ROSIGLITAZONA (AVANDIA)

Spc suppl protection certif: C200100002

Filing date: 20010110

Expiry date: 20130826

Effective date: 20031008